Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA

• Published in: Drugs - Real World Outcomes Vol. 10; no. 3; pp. 395 - 404
• Main Authors: Barzi, Afsaneh, Lin, Feng, Song, Jinlin, Lam, Clara, Nie, Xiaoyu, Noman, Ahmed, Kwong, Winghan J.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2023; Springer; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Cancer; Cancer therapies; Chemotherapy; Comorbidity; Costs; Drug therapy; Economic aspects; Evaluation; Forecasts and trends; Gastric cancer; Health care policy; Internal Medicine; Medical care, Cost of; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Methods; Monoclonal antibodies; Original; Original Research Article; Patients; Pharmacology/Toxicology; Pharmacotherapy; Pharmacy; Stomach cancer; Targeted cancer therapy; United States; United States > US
• ISSN: 2199-1154; 2198-9788
• DOI: 10.1007/s40801-023-00378-y

Background Trastuzumab in combination with chemotherapy is the standard first-line (1L) treatment for HER2+ metastatic gastric cancer (mGC) in the USA. Objective This study characterizes the real-world treatment patterns, healthcare resource use (HRU), and costs in patients with HER2+ mGC post-1L trastuzumab before approval of fam-trastuzumab deruxtecan-nxki. Patients and methods This retrospective study used the IQVIA PharMetrics ® Plus Database (October 2014–September 2019) to identify adults with HER2+ mGC who discontinued trastuzumab-based regimens in 1L. Patient characteristics, second-line (2L) treatment patterns, and treatment duration were summarized. HRU and costs before and after discontinuation of 1L trastuzumab-based regimens as well as during 2L treatment were described. Results Of the 190 HER2+mGC patients who discontinued 1L trastuzumab-based regimens, 136 (71.58%) initiated 2L treatments. Trastuzumab-based regimens were the most common in 2L (50.74%), followed by ramucirumab + paclitaxel (19.85%). The median time to 2L discontinuation was 2.37 months. During a mean follow-up of 9.8 months, mean per-patient-per-month (PPPM) healthcare costs post-1L trastuzumab-based regimens were higher in patients receiving 2L treatment than those without subsequent treatment (US$25,178 vs. US$14,812). The mean PPPM cost during 2L treatment was US$30,838, primarily driven by outpatient infusion costs (US$22,262). Conclusions The short duration of 2L treatment observed in this study is consistent with a lack of effective treatments post-1L trastuzumab prior to 2020. Re-use of trastuzumab treatment was common despite its limited efficacy and high treatment cost. The findings highlight the unmet medical needs and substantial burden faced by patients with HER2 +mGC previously treated with trastuzumab.